The latest price target for Arcturus Therapeutics (NASDAQ:ARCT) was reported by Cantor Fitzgerald on September 9, 2024. The analyst firm set a price target for $0.00 expecting ARCT to fall to within 12 months (a possible -100.00% downside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for Arcturus Therapeutics (NASDAQ:ARCT) was provided by Cantor Fitzgerald, and Arcturus Therapeutics reiterated their overweight rating.

The last upgrade for Arcturus Therapeutics Holdings Inc happened on May 11, 2023 when HC Wainwright & Co. raised their price target to $51. HC Wainwright & Co. previously had a neutral for Arcturus Therapeutics Holdings Inc.

The last downgrade for Arcturus Therapeutics Holdings Inc happened on November 10, 2022 when Baird changed their price target from N/A to $18 for Arcturus Therapeutics Holdings Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arcturus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arcturus Therapeutics was filed on September 9, 2024 so you should expect the next rating to be made available sometime around September 9, 2025.

While ratings are subjective and will change, the latest Arcturus Therapeutics (ARCT) rating was a reiterated with a price target of $0.00 to $0.00. The current price Arcturus Therapeutics (ARCT) is trading at is $21.50, which is out of the analyst’s predicted range.